2'-羟基苯乙酮-5'-羧酸 | 16357-40-7

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物 - 环羧酸
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2'-羟基苯乙酮-5'-羧酸
• 中文别名: 3-乙酰基-4-羟基苯甲酸
• 英文名称: 3-acetyl-4-hydroxybenzoic acid
• CAS: 16357-40-7
• 化学式: C₉H₈O₄
• mdl: MFCD00532680
• 分子量: 180.16
• InChiKey: FPBXWXGOFQSROI-UHFFFAOYSA-N

物化性质

• 熔点：
  241-242℃
• 沸点：
  374.9±32.0 °C(Predicted)
• 密度：
  1.365

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2918990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温下应保持干燥和密封保存。

制备方法与用途

用途

2′-羟基苯乙酮-5′-羧酸用作研究用化合物。

反应信息

• 作为反应物：
  描述：

  2'-羟基苯乙酮-5'-羧酸 在 氢氧化钾 、 sodium hydroxide 、 溴 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 2.0h， 生成 4-oxo-2-phenyl-4H-chromene-6-carboxylic acid
  参考文献：
  名称：

  Synthesis of carboxylated flavonoids as new leads for LTD4 antagonists

  摘要：

  A series of 3'- and 5'-carboxylated chalcones, 6- or 8-carboxylated flavones and 6-carboxylated flavanones, -flavanols and -flavans were prepared. The compounds were tested for their inhibitory activities against leukotriene D-4 (LTD(4)) induced contraction of guinea-pig ileum. A new and convenient synthetic route to 3-acetyl-2-hydroxybenzoic acid (1d), a key intermediate for the synthesis of 3'-carboxy-2'-hydroxychalcones and 8-carboxylated flavones, was developed. The activities of the tested compounds ranged from 0 to 63% inhibition at 10(-5) M drug concentration against a single challenge of 10(-8) M LTD(4). Several compounds were tested in a radioligand binding assay against [H-3]LTD(4) on guinea-pig lung membrane. The quinoline-containing chalcone 12 and flavone 17 were found to exhibit significant but weak affinities for LTD(4) receptors with pK(D)-values of 4.95 and 4.83, respectively, and are interesting lead structures for the development of rigid LTD(4) antagonists. In contrast, the rest of the compounds tested in the binding assay did not show significant displacement of the radioligand, implying that for these compounds the functional activity is probably not caused by competitive antagonism at the LTD(4) receptor. The exact mechanism of the relaxant activity remains unclear.

  DOI：

  10.1016/s0223-5234(97)89849-2
• 作为产物：
  描述：

  4-ethoxy-3-(2,2,2-trichloro-1-hydroxy-ethyl)-benzoic acid 在 氢碘酸 作用下， 生成 2'-羟基苯乙酮-5'-羧酸
  参考文献：
  名称：

  Chattaway; Calvet, Journal of the Chemical Society, 1927, p. 692

  摘要：

  DOI：

文献信息

• Synthesis and Structure−Activity Relationships of Carboxylated Chalcones:  A Novel Series of <i>CysLT</i>₁ (LTD₄) Receptor Antagonists
  作者：Mariël E. Zwaagstra、Hendrik Timmerman、Masahiro Tamura、Tsutomu Tohma、Yasushi Wada、Kazuhiro Onogi、Ming-Qiang Zhang

  DOI：10.1021/jm960628d

  日期：1997.3.1

  The synthesis and CysLT1 antagonistic activities of a new series of 2-, 3-, and 4-(2-quinolinylmethoxy)- and 3- and 4-[2-(2-quinolinyl)ethenyl]-substituted, 2'-, 3'-, 4'-, or 5'-carboxylated chalcones are described. Structure-activity relationship studies indicate a preference for the presence of a negatively charged (acidic) moiety, although in some cases nitrile or ester analogues also exhibit moderate

  一系列新的2-，3-和4-（2-喹啉基甲氧基）-和3-和4- [2-（2-喹啉基）乙烯基]-取代的2'-，3的合成及CysLT1拮抗活性描述了'-，4'-或5'-羧基查耳酮。结构-活性关系研究表明，优选带负电的（酸性）部分，尽管在某些情况下腈或酯类似物也具有中等活性。喹啉部分可以在3-或4-位被取代。用其他芳香族基团取代该杂环会导致化合物具有可比的亲和力[2-（7-氯喹啉），1-（1-甲基-2-苯并咪唑）或1-（2-苯并噻唑）]或具有较低的活性[1 -（1-乙氧基乙基）-2-苯并咪唑，2-萘基或苯基]。喹啉和查耳酮部分可以通过乙烯基或甲氧基间隔基连接。对于3-和4-取代的查耳酮，查耳酮B环上的酸性部分可以连接至2'-，3'-，4'-或5'-位置。没有一般模式可以指定哪个取代位置产生最有效的化合物。该系列包含几种有效的CysLT1受体拮抗剂，其K（D）值接近纳摩尔范围，通过[3H] LTD4
• [EN] 3-SUBSTITUTED-1H-INDOLE, 3-SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE AND 3-SUBSTITUTED-1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES<br/>[FR] COMPOSÉS 1H-INDOLE SUBSTITUÉ EN POSITION 3, 1H-PYRROLO[2,3-B]PYRIDINE SUBSTITUÉE EN POSITION 3 ET 1H-PYRROLO[3,2-B]PYRIDINE SUBSTITUÉE EN POSITION 3, LEUR UTILISATION COMME MTOR KINASE ET INHIBITEURS DE LA PI3 KINASE, ET LEURS SYNTHÈSES
  申请人：WYETH LLC

  公开号：WO2010030727A1

  公开（公告）日：2010-03-18

  The invention relates to 3-substituted-1H-indole, 3-substituted-1H-pyrrolo[2,3-b]pyridine, and 3-substituted-1H-pyrrolo[3,2-b]pyridine compounds of the Formula (I): or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.

  这项发明涉及Formula (I)的3-取代-1H-吲哚、3-取代-1H-吡咯并[2,3-b]吡啶和3-取代-1H-吡咯并[3,2-b]吡啶化合物，或其药学上可接受的盐，其中组成变量如本文所定义，包括这些化合物的组合物，以及制备和使用这些化合物的方法。
• 含咪唑稠合三环类化合物及其应用
  申请人：广州必贝特医药技术有限公司

  公开号：CN107383024B

  公开（公告）日：2018-06-08

  本发明公开了具有式(I)所示结构的含咪唑稠合三环类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子。该类化合物具有调节IDO1活性的作用，这类化合物通过阻断免疫检查点IDO1，可以增强T细胞激活，用于治疗IDO1介导的免疫抑制，从而能够成为治疗恶性肿瘤的有效药物。与检查点蛋白的抗体药物或其他抗癌药物合用，可以增强抗癌效果。同时也有潜力有效治疗与IDO1异常有关的免疫抑制性疾病，有较大的应用价值。
• Sulfonamide-substituted chromans, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them
  申请人：Hoechst Aktiengesellschaft

  公开号：US06191164B1

  公开（公告）日：2001-02-20

  Sulfonamide-substituted chromans, processes for their preparation, their use as a medicament or a diagnostic, and medicament comprising them Chromans of the formula I and of the formula 1a having the meanings R(A), R(B), R(C) and R(1) to R(8) indicated in the claims are outstandingly suitable for preparing a medicament for blocking the K+ channel which is opened by cyclic adenosine monophosphate (cAMP); and further for preparing a medicament for inhibiting gastric acid secretion; for the treatment of ulcers of the stomach and of the intestinal region, in particular of the duodenum, for the treatment of reflux esophagitis, for the treatment of diarrheal illnesses, for the treatment and prevention of all types of arrhythmias including ventricular and supraventricular arrhythmias, and for the control of reentry arrhythmias and for the prevention of sudden heart death as a result of ventricular fibrillation.

  磺胺基取代的色苷，其制备方法，其用作药物或诊断的用途，以及包含它们的药物 具有下式I的色苷和下式1a的色苷，其中在权利要求中指示的R(A)、R(B)、R(C)和R(1)到R(8)的含义，非常适合制备用于阻断由环磷酸腺苷单磷酸（cAMP）打开的K+通道的药物；进一步用于制备用于抑制胃酸分泌的药物；用于治疗胃和肠道溃疡，特别是十二指肠的药物；用于治疗反流性食道炎；用于治疗腹泻疾病；用于治疗和预防包括室性和房性心律失常在内的所有类型心律失常；用于控制再入性心律失常和预防由室颤引起的突发心脏死亡。
• INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION
  申请人：Antabio SAS

  公开号：EP3628672A1

  公开（公告）日：2020-04-01

  The invention relates to a compound which is an indane according to Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, L, M, Ⓐ, n, p, and q are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics.

  该发明涉及一种化合物，其为根据式（I）的茚烷，或其药学上可接受的盐，其中R1、R2、R3、R4、R5、R6、L、M、Ⓐ、n、p和q如本文所定义。这些化合物在抗菌感染的治疗中非常有用，可以作为独立抗生素使用，也可以与其他抗生素联合使用。